WO2008070047A3 - Immunogènes dans des cellules souches cancéreuses - Google Patents

Immunogènes dans des cellules souches cancéreuses Download PDF

Info

Publication number
WO2008070047A3
WO2008070047A3 PCT/US2007/024787 US2007024787W WO2008070047A3 WO 2008070047 A3 WO2008070047 A3 WO 2008070047A3 US 2007024787 W US2007024787 W US 2007024787W WO 2008070047 A3 WO2008070047 A3 WO 2008070047A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
cancer stem
immunogens
cancer
cells
Prior art date
Application number
PCT/US2007/024787
Other languages
English (en)
Other versions
WO2008070047A2 (fr
Inventor
Ramila Philip
Lorraine Holowach Keller
Original Assignee
Immunotope Inc
Ramila Philip
Lorraine Holowach Keller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotope Inc, Ramila Philip, Lorraine Holowach Keller filed Critical Immunotope Inc
Publication of WO2008070047A2 publication Critical patent/WO2008070047A2/fr
Publication of WO2008070047A3 publication Critical patent/WO2008070047A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des compositions et des procédés pour la prévention, le traitement, et le diagnostic de cancer, particulièrement des cellules souches cancéreuses. L'invention concerne des peptides, des polypeptides, et des polynucléotides qui peuvent être utilisés pour stimuler une réponse des CTL contre des cellules cancéreuses, en particulier des cellules souches cancéreuses.
PCT/US2007/024787 2006-12-05 2007-12-04 Immunogènes dans des cellules souches cancéreuses WO2008070047A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/633,858 US20070248628A1 (en) 2005-12-06 2006-12-05 Immunogens in cancer stem cells
US11/633,858 2006-12-05

Publications (2)

Publication Number Publication Date
WO2008070047A2 WO2008070047A2 (fr) 2008-06-12
WO2008070047A3 true WO2008070047A3 (fr) 2008-11-27

Family

ID=39492835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/024787 WO2008070047A2 (fr) 2006-12-05 2007-12-04 Immunogènes dans des cellules souches cancéreuses

Country Status (2)

Country Link
US (1) US20070248628A1 (fr)
WO (1) WO2008070047A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519910A (ja) 2004-01-28 2007-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドの同定および定量方法
CA2644136A1 (fr) * 2006-02-27 2007-09-07 The Johns Hopkins University Traitement anticancereux utilisant des inhibiteurs de gamma-secretases
WO2009047488A1 (fr) * 2007-10-09 2009-04-16 The Council Of The Queensland Institute Of Medical Research Procédé de criblage pour des agents anticancéreux
WO2009149094A2 (fr) * 2008-06-02 2009-12-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide egfr défini par lymphocyte t cytotoxique et peptide dérivé optimisé
US20110171219A1 (en) * 2008-09-19 2011-07-14 Fahar Merchant Treating cancer stem cells using targeted cargo proteins
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
CA2772551A1 (fr) 2009-08-26 2011-03-03 Immunotope, Inc. Immunogenes cytotoxiques induisant des lymphocytes t pour prevenir, traiter et diagnostiquer un cancer
WO2011038300A1 (fr) * 2009-09-24 2011-03-31 The Trustees Of Columbia University In The City Of New York Cellules souches cancéreuses, kits et procédés
CA2798432A1 (fr) 2010-05-06 2011-11-10 Novartis Ag Compositions et procedes d'utilisation d'anticorps therapeutiques diriges contre la proteine 6 liee a la lipoproteine de basse densite (lrp6)
JP2013527761A (ja) 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）多価抗体の組成物および使用方法
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US9945842B2 (en) 2010-09-03 2018-04-17 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
EP2446895A1 (fr) * 2010-10-01 2012-05-02 Stemgen S.P.A. Expression de récepteur EPH dans les cellules souches de tumeur
WO2012104836A1 (fr) * 2011-01-31 2012-08-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Snx9 en tant que nouveau biomarqueur pour l'inflammation chronique et l'immunosuppression associée et nouveau régulateur de l'expression des récepteurs de cellules t et fonction
TW201302800A (zh) 2011-06-10 2013-01-16 Oncotherapy Science Inc Ｓｅｍａ５ｂ胜肽及含其之疫苗
EP2755679B1 (fr) * 2011-09-13 2017-08-02 Immunotope, Inc. Immunogènes induisant des lymphocytes t cytotoxiques utilisés pour la prévention, le traitement et le diagnostic du cancer
EP3290442A1 (fr) 2011-11-04 2018-03-07 Novartis AG Constructions de protéine 6 liée à la lipoprotéine de basse densité (lrp6) prolongeant leur demi-vie
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
CN104812446B (zh) * 2012-10-24 2020-04-14 密歇根大学董事会 癌干细胞接种和治疗
AU2013202668B2 (en) * 2012-12-24 2014-12-18 Adelaide Research & Innovation Pty Ltd Inhibition of cancer growth and metastasis
KR20160106175A (ko) 2014-01-13 2016-09-09 버그 엘엘씨 에놀라아제 1 조성물들 및 이의 용도
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
US10000533B2 (en) 2014-06-20 2018-06-19 Immatics Biotechnologies Gmbh Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
KR20170095284A (ko) * 2014-12-09 2017-08-22 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 종양 항원 펩티드
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
IL260877B2 (en) 2015-03-27 2023-10-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against different types of tumors
GB201512703D0 (en) 2015-07-20 2015-08-26 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
CA3020162A1 (fr) 2016-04-06 2017-10-12 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunotherapie contre la leucemie myeloide aigue (lma) et d'autres cancers
CA3079837A1 (fr) * 2017-11-01 2019-05-09 The Board Of Trustees Of The Leland Stanford Junior University Procede de detection d'analyte

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972643A (en) * 1994-06-17 1999-10-26 Fred Hutchinson Cancer Research Center Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) * 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5645994A (en) * 1990-07-05 1997-07-08 University Of Utah Research Foundation Method and compositions for identification of species in a sample using type II topoisomerase sequences
DE4143467C2 (de) * 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US6168804B1 (en) * 1995-06-07 2001-01-02 University Of Alberta Method for eliciting Th1-specific immune response
US6140464A (en) * 1995-06-07 2000-10-31 Ludwig Institute For Cancer Research Nonapeptides that bind a HLA-A2.1 molecule
CA2230795A1 (fr) * 1995-09-07 1997-03-13 Khandan Keyomarsi Variantes de la cycline e et leur utilisation
US7270819B2 (en) * 1997-05-05 2007-09-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereof
US6548064B1 (en) * 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
WO2002046416A2 (fr) * 2000-12-04 2002-06-13 Argonex Pharmaceuticals Immunogenes induisant une reponse des lymphocytes t cytotoxiques pour la prevention, le traitement et le diagnostic de cancers
AU2002311787A1 (en) * 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972643A (en) * 1994-06-17 1999-10-26 Fred Hutchinson Cancer Research Center Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor

Also Published As

Publication number Publication date
US20070248628A1 (en) 2007-10-25
WO2008070047A2 (fr) 2008-06-12

Similar Documents

Publication Publication Date Title
WO2008070047A3 (fr) Immunogènes dans des cellules souches cancéreuses
ZA200900956B (en) Tumor suppression using placental stem cells
WO2010069532A8 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2006103666A3 (fr) Polypeptides bid isoles, polynucleotides les codant et anticorps diriges contre ces polypeptides, methodes d'utilisation pour induire l'arret du cycle cellulaire ou l'apoptose
WO2009108730A3 (fr) Formes de rifaximine et utilisations correspondantes
WO2008014200A3 (fr) Compositions de cyclosporine
WO2008058239A3 (fr) Spink1 en tant que marqueur du cancer de la prostate et ses utilisations
WO2007118149A3 (fr) Thiazole et thiophene analogues et leur utilisation pour traiter des maladies auto-immunes et des cancers
WO2009036246A3 (fr) Immunogènes qui induisent des lymphocytes t cytotoxiques et leur utilisation dans la prévention, le traitement et le diagnostic du cancer
WO2010132370A3 (fr) Peptides solubles de la famille trem-1 et procédés d'utilisation
WO2008036929A3 (fr) Complexe permettant de tansférer une substance anionique dans une cellule
EP2007410A4 (fr) Procédé de prévention ou de réduction du risque ou de l'incidence de cancer en utilisant des peptides à base de protéines ntp
PT2315773T (pt) Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente
WO2008066784A3 (fr) Expression de foxp3 par des cellules cancéreuses
WO2006130433A3 (fr) Traitement de l'ischemie au moyen de cellules souches
WO2008027600A3 (fr) Compositions d'imatinib
WO2008043052A3 (fr) Anticorps humains neutralisant le métapneumovirus humain
WO2008113515A3 (fr) Antagonistes sélectifs de hutnfr1
WO2008013966A3 (fr) Utilisation de 8-quinolinol et de ses analogues pour cibler des cellules souches cancéreuses
WO2007122382A3 (fr) Lycopène pour le traitement d'une dysmétabolie
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
WO2011075606A3 (fr) Variants de polypeptide hyperglycosylé et procédés d'utilisation
WO2007144057A3 (fr) Carbone antimicrobien

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07862465

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07862465

Country of ref document: EP

Kind code of ref document: A2